182 results on '"Caviglia, G.P."'
Search Results
2. T.11.8: EFFECT OF PERIODONTITIS AND PERIODONTAL THERAPY ON GUT MICROBIOTA
3. Effect of Periodontitis and Periodontal Therapy on Oral and Gut Microbiota
4. Treatment of hepatitis D: an unmet medical need
5. Efficacy of nivolumab monotherapy in cirrhotic patients with advanced hepatocellular carcinoma: a single-center retrospective study
6. Magnetic Resonance-based fibrosis markers in patients with Non-Alcoholic Fatty Liver Disease: Exploratory data from the Turin cohort
7. A nutrigenetic precision approach for the management of NAFLD
8. Low adherence to Mediterranean Diet is associated to sCD163 levels in patients with MAFLD
9. The use of AGILE 3+ and AGILE 4 for the prediction of advanced fibrosis and cirrhosis in patients with Non-Alcoholic Fatty Liver Disease
10. T.07.3 PROGNOSTIC VALUE OF LIVER STIFFNESS AND FIB-4 SCORE IN INDIVIDUALS WITH CIRRHOSIS DUE TO NON-ALCOHOLIC FATTY LIVER DISEASE WITHOUT PREVIOUS LIVER DECOMPENSATION
11. Interferon gamma-induced protein 10 levels are associated with insulin resistant components in subjects with non-alcoholic fatty liver disease
12. Social jetlag and mediterranean diet adherence are associated to liver fibrosis in patients with non-alcoholic fatty liver disease
13. Echocardiography-based markers of subclinical cardiac dysfunction in individuals with Non-Alcoholic Fatty Liver Disease and preserved ejection fraction: Interim data from a prospective study
14. Prognostic value of simple non-invasive tests for the risk stratification of hcc development in patients with cirrhosis due to non-alcoholic fatty liver disease
15. Development and validation of an artificial intelligence PIVKA-II-based model for the prediction of hepatocellular carcinoma development in patients with HCV-related cirrhosis successfully treated with direct-acting antivirals
16. T.03.3 FECAL SMALL NON-CODING RNAS AND MICROBIOME CHARACTERIZE PATIENTS WITH CELIAC DISEASE
17. Irisin alleviates liver oxidative stress in non-obese, non-diabetic individuals with Non-Alcoholic Fatty Liver Disease
18. Steroidomic profiles across the spectrum of liver damage in non-alcoholic fatty liver disease
19. MiRNome profiling of circulating extracellular vesicles in patients with chronic hepatitis delta treated with pegylated interferon alpha
20. Liver cancer-specific isoform of serine protease inhibitor Kazal for the detection of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
21. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?
22. OC.09.2 VITAMIN D-RELATED GENETICS AS PREDICTOR OF RESPONSE TO ADALIMUMAB IN CROHN’S DISEASE
23. Increased serum ferritin levels predict long-term mortality in patients with NAFLD
24. Efficacy of transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome – chronic kidney disease
25. Risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis of viral etiology evaluated by the association of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II) and glypican-3 (GPC-3)
26. Terlipressin vs noradrenaline for the treatment of hepatorenal syndrome in patients with acute-on-chronic liver failure: a 5-year retrospective analysis
27. Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
28. Risk of contrast-induced acute kidney injury in cirrhotic patients undergoing computed tomography: myth or reality?
29. OC.03.6: STUDY OF CORRELATION BETWEEN POLYMORPHISMS OF VITAMIN D METABOLISM GENES AND PERIANAL DISEASE IN CROHN'S DISEASE.
30. Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease
31. Response to treatment and mortality in patients with acute-on-chronic liver failure according to the new definition of hepatorenal syndrome: a single center 3-year retrospective analysis
32. Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience
33. Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D
34. Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection
35. Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in patients with chronic hepatitis D
36. Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy
37. Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR
38. Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or antagonist II
39. Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy
40. Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology
41. Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
42. Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease
43. Hepatitis B core-related antigen levels during nucleos(t)ide analogues or pegylated-interferon treatment in patients chronically infected with HBV genotype-D
44. Etiology of chronic liver disease and HCC biomarkers
45. Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease
46. A Novel Approach for Hepatitis Delta Virus Viremia Quantification by Droplet Digital PCR Assay
47. FRI-275 - Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection
48. FRI-259 - Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D
49. Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection
50. P0364 : Clinic evaluation of circulating micrornas as potential biomarkers of hepatocellular carcinoma in patients with HBV chronic infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.